Alisertib (MLN8237) in Combination With Weekly Paclitaxel in East Asian Patients With Advanced Solid Tumors
Status:
Terminated
Trial end date:
2017-05-23
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and tolerability and determine the MTD to
subsequently define an RP2D of alisertib in combination with weekly paclitaxel in East Asian
participants with advanced solid tumors.